TY - JOUR
T1 - IMMUnity Unveiled
T2 - A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET
AU - Gugu, Mitilda
AU - Acharya, Shubhra
AU - Pira, Dogukan
AU - Poletti, Simona
AU - di Flora, Alessia
AU - Saksida, Tamara
AU - Pilipenko, Vladimirs
AU - Romero-Ramos, Marina
AU - Marino, Franca
AU - Muñoz Delgado, Laura
AU - Nikolovski, Neda
AU - Gursoy Ozdemir, Yasemin
AU - Lawson, Dale
AU - Comi, Cristoforo
AU - Figueira, Inês
N1 - Funding
This project has received funding from the European Union’s Framework Programme for Research & Innovation as part of the COST Action under grant agreement No CA21117 (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET]), as supported by the COST Association (European Cooperation in Science and Technology). The
authors will also like to acknowledge the following financial support: M.G (University of Elbasan “Aleksandër Xhuvani”); S.A. (#AFR14566210 – from the Fonds National de la Recherche (FNR) of Luxembourg); I.F. (2022.00151.CEECIND – from Fundação para a Ciência e Tecnologia (FCT) of Portugal); A.F. (PhD course in Clinical and Experimental Medicine and Medical Humanities from University
of Insubria); N.N. (451-03-47/2023-01/200007 from Ministry of Science, Technological Development, and Innovations, Republic of Serbia);
L.M.D. is supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III (Spain); C.C. is supported by the
AGING PROJECT —Department of Excellence— Università del Piemonte Orientale.
Publisher Copyright:
Copyright: © 2025 Gugu M et al.
PY - 2025/1/23
Y1 - 2025/1/23
N2 - Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.
AB - Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.
KW - immune response
KW - network
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85217444470&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/39911303/
U2 - 10.12688/openreseurope.17547.2
DO - 10.12688/openreseurope.17547.2
M3 - Letter
C2 - 39911303
AN - SCOPUS:85217444470
SN - 2732-5121
VL - 4
JO - Open Research Europe
JF - Open Research Europe
M1 - 119
ER -